What's in Vertex Pharmaceuticals Inc.'s pipeline?

Vertex Pharmaceuticals Inc. has 6 drugs in our index: 6 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Vertex Pharmaceuticals Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vertex.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Vertex Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Vertex Pharmaceuticals Inc. (VRTX) pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

VRTX (NASDAQ) 6 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Alyftrek	VANZACAFTOR	marketed	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]		Respiratory	2026-01-01
Journavx	SUZETRIGINE	marketed	Sodium Channel Blocker [EPC]		Metabolic	2025-01-01
Trikafta (Copackaged)	ELEXACAFTOR	marketed		Cystic fibrosis transmembrane conductance regulator	Respiratory	2019-01-01
Symdeko (Copackaged)	TEZACAFTOR	marketed		CFTR	Respiratory	2018-01-01
Kalydeco	IVACAFTOR	marketed	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	Cystic fibrosis transmembrane conductance regulator	Respiratory	2012-01-01
SYMDEKO (COPACKAGED)	IVACAFTOR, TEZACAFTOR	marketed			Other

Therapeutic area mix

Respiratory · 4
Metabolic · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-06 — Trikafta (Copackaged) · 8354427 · US
2026-07-06 — Symdeko (Copackaged) · 8354427 · US
2026-12-28 — Symdeko (Copackaged) · 8410274 · US
2026-12-28 — Symdeko (Copackaged) · 9931334 · US
2026-12-28 — Symdeko (Copackaged) · 9670163 · US
2026-12-28 — Trikafta (Copackaged) · 9931334 · US
2026-12-28 — Trikafta (Copackaged) · 9670163 · US
2026-12-28 — Trikafta (Copackaged) · 8410274 · US
2026-12-28 — Trikafta (Copackaged) · 8754224 · US
2026-12-28 — Symdeko (Copackaged) · 8754224 · US
2027-04-09 — Symdeko (Copackaged) · 10239867 · US
2027-04-09 — Trikafta (Copackaged) · 10022352 · US
2027-04-09 — Trikafta (Copackaged) · 10239867 · US
2027-04-09 — Trikafta (Copackaged) · 11639347 · US
2027-04-09 — Trikafta (Copackaged) · 9974781 · US
2027-04-09 — Symdeko (Copackaged) · 10022352 · US
2027-04-09 — Symdeko (Copackaged) · 11639347 · US
2027-04-09 — Symdeko (Copackaged) · 9974781 · US
2027-05-01 — Symdeko (Copackaged) · 7645789 · US
2027-05-01 — Trikafta (Copackaged) · 8623905 · US
2027-05-01 — Trikafta (Copackaged) · 7645789 · US
2027-05-01 — Trikafta (Copackaged) · 8598181 · US
2027-05-01 — Symdeko (Copackaged) · 8623905 · US
2027-05-01 — Symdeko (Copackaged) · 8598181 · US
2027-05-20 — Trikafta (Copackaged) · 7495103 · US
2027-05-20 — Symdeko (Copackaged) · 7495103 · US
2027-06-03 — Symdeko (Copackaged) · 7776905 · US
2027-06-03 — Trikafta (Copackaged) · 7776905 · US
2027-08-05 — Symdeko (Copackaged) · 8324242 · US
2027-08-05 — Trikafta (Copackaged) · 8324242 · US

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Vertex Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Vertex Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vertex. Accessed 2026-05-14.